Balsalazide Disodium NDC 72162-2095

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2095Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2095Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2095-2	72162209502	280 CAPSULE in 1 BOTTLE (72162-2095-2)Marketed from Dec 28, 2007

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Balsalazide Disodium
Generic name (nonproprietary): balsalazide disodium
Active ingredients: Balsalazide disodium — 750 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077883
Marketing start: Dec 28, 2007
Listing expires: Dec 31, 2026
Other FDA classes: Aminosalicylic Acids (Chemical structure)
Identifiers: Product ID 72162-2095_fa1fdea0-35a4-46c7-ada0-3f5c71955075SPL ID fa1fdea0-35a4-46c7-ada0-3f5c71955075SPL set ID cd73c9f1-d83b-4206-b2c6-1bd111e11263RxCUI 885857UNII 1XL6BJI034
Pharmacologic class: Aminosalicylate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162209502 followed by a unit qualifier and the quantity

Package 72162-2095-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 2, 2025.

Indications (excerpt from the label)

Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Limitations of Use Safety and effectiveness of balsalazide beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established. Balsalazide is an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. ( 1 ) Limitations of Use: Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077883

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077883
Product	Strength	Form · route	Labeler	Product NDC
Balsalazide Disodium	Balsalazide disodium 750 mg/1	CapsuleOral	AvPAK	50268-102
Balsalazide Disodium	Balsalazide disodium 750 mg/1	CapsuleOral	Apotex Corp.	60505-2575